New Standard of Care in Pancreatic Cancer?

New Standard of Care in Pancreatic Cancer?

• FOLFIRINOX chemoterapie (5-fluorouracil, leukovorinu, irinotekan a oxaliplatina)
• Conducted in 342 patients with metastatic pancreatic cancer, the trial showed a significant improvement in median OS — from 6.8 months with gemcitabine to 11.1 months with FOLFIRINOX. PFS also improved, from 3.4 to 6.4 months. The authors said these survival times were the best ever seen in metastatic pancreatic cancer.

Related articles

• Pancreatic Cancer Survival Statistics and Results

  ---

• Pancreatic Cancer Information

  ---

• Pancreatic Cancer Treatments

  ---

• Pancreatic cancer drug cocktail boosts survival

  ---

• New treatment protocol extends survival in some cases of once inoperable pancreatic cancer

  ---